Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer (CRPC)

NCT01995058 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT01995058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01995058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Lead sponsor
Exelixis
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2014
Completion date
November 30, 2014
Enrollment
54 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer, prostate cancer, prostatic neoplasms